ALPHAPORT.AI
🇺🇸TerrAscend Corp.TSNDF
USDUSD
SectorHealth CareIndustryPharma
Management
Ziad Ghanem
CEO

Company information

Ticker
TSNDF
Country
United States
Sector
Health Care
Industry
Pharma

TerrAscend Business Summary

TerrAscend Corp. (TSNDF) is a vertically integrated North American cannabis operator that generates revenue through a dual-channel model of direct-to-consumer retail sales and wholesale distribution of branded products. The company’s primary business segments are concentrated in high-growth, limited-license U.S. markets—specifically New Jersey, Pennsylvania, Maryland, and Ohio—complemented by a licensed cultivation and retail footprint in Canada. By controlling the entire "seed-to-sale" value chain, TerrAscend produces and markets a diverse portfolio of premium brands, including The Apothecarium, Gage Cannabis, Kind Tree, and Valhalla Confections. Within the North American market, the company competes directly with large-scale multi-state operators (MSOs) such as Curaleaf Holdings, Trulieve Cannabis Corp., and Green Thumb Industries. TerrAscend differentiates itself by maintaining a leading market share in the Northeast and achieving superior operational efficiency, often reporting gross margins that outpace its larger peers. Founded by Michael Nashat and Basem Hanna, TerrAscend is currently led by Executive Chairman Jason Wild and CEO Ziad Ghanem. Wild, the founder of JW Asset Management, brings a specialized pedigree in pharmaceutical investing and capital allocation, having served as the company’s primary financial architect since 2017. CEO Ziad Ghanem, appointed in 2023, provides deep operational expertise from his 15-year tenure at Walgreens Boots Alliance and his previous role as President of Parallel. The leadership team also includes Interim CFO Alisa Campbell, who previously held senior financial roles at Cresco Labs, and Chief People and Legal Officer Lynn Gefen, alongside SVP and Chief Information Officer David Wheeler. The company’s strategic trajectory is supported by a high-profile board of directors, including Heron Therapeutics CEO Craig Collard and pharmaceutical executive Ed Schutter, with significant institutional backing from JW Asset Management and early-stage investment from Canopy Growth.

Updated 2026-07-31 · US SEC company filings
Financial Metric TrendsQuarterly⌄
Business Overview is available publicly. Financials, KPIs, reports, transcripts and the rest of Research require the Research tier.